Vaxcyte and Sutro finalize Form Definitive Agreement; amend license terms

Vaxcyte, Inc.

On Sep 28, 2023, Vaxcyte and Sutro mutually agreed on the Form Definitive Agreement to become effective if Vaxcyte exercises the option to source extract.
Concurrently, the companies entered the 2023 Amendment to the Sutro License Agreement, modifying royalty reductions, IP prosecution, and royalty payment reporting.
The previously agreed $5.0M cash payment to Sutro remains due within five business days after mutual agreement on the Form Definitive Agreement.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

Vaxcyte, Inc. amended 2023 Amendment with Sutro Biopharma, Inc. (effective 2023-09-28).

Action: amendment
Agreement: collaboration
Counterparty: Sutro Biopharma, Inc.
Effective: 2023-09-28

Exact text from the filing

Concurrent with the Companies’ mutual agreement upon the Form Definitive Agreement on September 28, 2023, the Companies entered into the 2023 Amendment.

View on SEC.gov

Browse all material agreements →

Vaxcyte, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-250816

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.